title: The detection of CMV pp65 and IE1 in glioblastoma multiforme.
abstract: Glioblastoma multiforme (GBM) is a highly lethal brain tumor affecting children and adults, with the majority of affected individuals dying from their disease by 2 years following diagnosis. Other groups have reported the association of cytomegalovirus (CMV) with GBM, and we sought to confirm these findings in a large series of patients with primary GBM from our institution. Immunohistochemical analysis of paraffin embedded tissue sections was performed on 49 newly diagnosed GBM tumors, the largest series reported to date. We confirmed the presence of CMV pp65 on 25/49 (51%) and of IE1 on 8/49 (16%) of these tumors. While pp65 and IE1 are generally found in the nucleus of cells that are permissibly infected by CMV, GBM in this series had mostly cytoplasmic staining, with only 16% having nuclear staining for one or both of these antigens. We infected GBM cell lines with a laboratory strain of CMV, and found that most of the staining was cytoplasmic, with some perinuclear localization of IE1. To test the potential for CMV infected GBM cells to be recognized by CMV pp65 and IE1 specific cytotoxic T lymphocytes (CTL), we used CMV infected GBM cell lines in cytotoxicity assays with human leukocyte antigen partially matched CMV CTL. Lysis of CMV infected GBM tumor cells was accentuated by pre-treating these cell lines with either the demethylating agent decitabine or interferon-γ, both of which were shown to increase MHC Class I and II expression on tumor cells in vitro. These studies confirm the presence of CMV pp65 or IE1 on approximately half of GBM, with the possibility that CMV positive tumor cells can be recognized by CMV pp65/IE1 specific T cells.
authors.affiliation: Department of Pediatrics, Penn State Hershey Children's Hospital, 500 University Drive, Room C7830, Hershey, PA 17033, USA. klucas@psu.edu
authors.forename: Kenneth G
authors.initials: KG
authors.lastname: Lucas
authors.forename: Lei
authors.initials: L
authors.lastname: Bao
authors.forename: Richard
authors.initials: R
authors.lastname: Bruggeman
authors.forename: Kimberly
authors.initials: K
authors.lastname: Dunham
authors.forename: Charles
authors.initials: C
authors.lastname: Specht
mesh_terms: D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000276:immunology / Q000821:virology*; D002469:Cell Separation; D003586:Cytomegalovirus Infections / Q000276:immunology; D005260:Female; D005434:Flow Cytometry; D005455:Fluorescent Antibody Technique; D005909:Glioblastoma / Q000276:immunology / Q000821:virology*; D006801:Humans; D017874:Immediate-Early Proteins / Q000032:analysis / Q000276:immunology*; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D010750:Phosphoproteins / Q000032:analysis / Q000276:immunology*; D014763:Viral Matrix Proteins / Q000032:analysis / Q000276:immunology*
chemical_list: C088645:IE1 protein, cytomegalovirus; D017874:Immediate-Early Proteins; D010750:Phosphoproteins; D014763:Viral Matrix Proteins; C065418:cytomegalovirus matrix protein 65kDa
references.citation: Curr Oncol Rep. 2003 Sep;5(5):372-9
references.pmid: 12895387
references.citation: J Natl Cancer Inst. 1986 Feb;76(2):223-8
references.pmid: 3080635
references.citation: Anticancer Res. 2000 Jan-Feb;20(1C):605-10
references.pmid: 10769703
references.citation: FEMS Microbiol Rev. 2004 Feb;28(1):59-77
references.pmid: 14975530
references.citation: J Neurooncol. 2007 Jan;81(2):139-48
references.pmid: 17004103
references.citation: J Biol Chem. 1996 Feb 16;271(7):3534-40
references.pmid: 8631958
references.citation: J Virol. 2007 Oct;81(19):10424-36
references.pmid: 17652378
references.citation: Neurosurgery. 1991 Jan;28(1):16-23
references.pmid: 1994273
references.citation: J Immunol. 2000 Oct 1;165(7):4105-11
references.pmid: 11034422
references.citation: J Neurosurg. 2004 Feb;100(2):310-9
references.pmid: 15086239
references.citation: J Immunol Methods. 2006 Mar 20;310(1-2):40-52
references.pmid: 16469329
references.citation: J Virol. 1997 Nov;71(11):8176-85
references.pmid: 9343168
references.citation: Neuro Oncol. 2008 Feb;10(1):10-8
references.pmid: 17951512
references.citation: Biol Blood Marrow Transplant. 2008 Oct;14(10):1156-1162
references.pmid: 18804046
references.citation: Science. 1998 Apr 10;280(5361):248-53
references.pmid: 9535648
references.citation: Mod Pathol. 2005 Jun;18(6):838-43
references.pmid: 15578071
references.citation: Viral Immunol. 2003;16(2):111-21
references.pmid: 12828864
references.citation: Clin Cancer Res. 2005 Aug 1;11(15):5515-25
references.pmid: 16061868
references.citation: Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):566-575
references.pmid: 17255279
references.citation: Neurosurgery. 1988 Dec;23(6):725-32
references.pmid: 2851116
references.citation: Clin Infect Dis. 2006 Nov 1;43(9):1143-51
references.pmid: 17029132
references.citation: J Interferon Cytokine Res. 2003 Jul;23(7):379-93
references.pmid: 14511464
references.citation: J Neuroimmunol. 1992 Jan;36(1):57-68
references.pmid: 1735769
references.citation: J Virol. 1988 Mar;62(3):1066-70
references.pmid: 2828655
references.citation: J Clin Apher. 2008;23(2):63-5
references.pmid: 18181166
references.citation: Acta Neuropathol. 2008 Jul;116(1):79-86
references.pmid: 18351367
references.citation: J Immunother. 2004 Sep-Oct;27(5):398-404
references.pmid: 15314549
references.citation: Immunol Rev. 2008 Apr;222:70-100
references.pmid: 18363995
references.citation: Br J Cancer. 2005 Feb 28;92(4):747-50
references.pmid: 15700045
references.citation: J Exp Med. 1999 Dec 6;190(11):1669-78
references.pmid: 10587357
references.citation: J Exp Med. 1988 Sep 1;168(3):919-31
references.pmid: 2844952
references.citation: Clin Liver Dis. 2005 May;9(2):191-211, v
references.pmid: 15831268
references.citation: J Gen Virol. 1986 Dec;67 ( Pt 12):2605-16
references.pmid: 3025342
references.citation: Neuro Oncol. 2001 Jul;3(3):152-8
references.pmid: 11465395
references.citation: Cancer Res. 2001 Feb 1;61(3):842-7
references.pmid: 11221866
references.citation: Lancet. 2002 Nov 16;360(9345):1557-63
references.pmid: 12443594
references.citation: Cancer Res. 2002 Jun 15;62(12):3347-50
references.pmid: 12067971
references.citation: EMBO J. 1994 Jun 15;13(12):2897-903
references.pmid: 8026474
references.citation: J Immunother. 2007 Jul-Aug;30(5):557-61
references.pmid: 17589296
references.citation: J Neurovirol. 2006 Apr;12(2):90-9
references.pmid: 16798670
references.citation: Int J Cancer. 2001 Oct 15;94(2):243-51
references.pmid: 11668505
references.citation: J Urol. 2003 Sep;170(3):998-1002
references.pmid: 12913758
references.citation: Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10399-404
references.pmid: 8816812
references.citation: J Neurooncol. 1998 Nov;40(2):151-60
references.pmid: 9892097
references.citation: N Engl J Med. 2008 Jul 31;359(5):539-41
references.pmid: 18669440
references.citation: J Biol Regul Homeost Agents. 2005 Jan-Jun;19(1-2):63-70
references.pmid: 16178276
references.citation: Immunol Rev. 2002 Oct;188:33-42
references.pmid: 12445279